The Cicada COVID-19 variant, an offshoot of the Omicron family, has emerged as a new concern in India. First spotted in South Africa in November 2024, it carries over 70 mutations compared to the original Wuhan strain, with around 50 of those located in the spike protein.

As of now, the variant has been detected in 22 countries, including India, where health officials are closely monitoring its spread. Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash.

Despite its extensive mutations, the Cicada variant is not confirmed to cause more severe illness than previous variants. This has led to some cautious optimism among health experts, though the situation remains fluid.

Dr. Robert Hopkins Jr. noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This statement underscores the uncertainty surrounding the variant’s potential impact.

The first confirmed case of the Cicada variant in the United States was reported in June 2025, with three patients confirmed by January 2026, all of whom recovered. This timeline highlights the variant’s rapid spread across borders.

Monitoring the spread of BA.3.2, as the Cicada variant is classified, is crucial. The CDC emphasized that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.

Details remain unconfirmed regarding the real-world data on the severity of illness caused by the Cicada variant. As health officials in India and around the world continue to assess the situation, the focus remains on understanding the implications of this new variant.

As the pandemic evolves, the emergence of the Cicada variant serves as a reminder of the ongoing challenges posed by COVID-19. Vigilance and adaptability in public health responses will be essential in managing its spread.

The post Cicada COVID Variant in India Raises Concerns appeared first on India News.

The cicada COVID variant, known as BA.3.2, is making waves across the United States as it spreads to at least 25 states. This heavily mutated strain of SARS-CoV-2 has raised significant concerns due to its potential to evade immunity from vaccines and previous infections.

First identified in South Africa in November 2024, BA.3.2 boasts an astonishing 70 to 75 mutations in its spike protein. These mutations may reduce the effectiveness of current vaccines against infection, although they are still expected to provide protection against severe disease.

As of February 2026, BA.3.2 has been detected in at least 23 countries, with a notable presence in Denmark, Germany, and the Netherlands, where it accounts for about 30% of cases. In the U.S., the variant was first detected in June 2025 in a traveler returning from the Netherlands.

Symptoms associated with BA.3.2 include cough, fever, sore throat, and loss of taste or smell, mirroring common COVID-19 symptoms. The variant spreads primarily through inhaling infectious respiratory particles and prolonged face-to-face interactions.

Despite its rapid spread, experts like Dr. Adolfo García-Sastre emphasize that there is currently no evidence suggesting BA.3.2 causes more severe disease or higher hospitalization rates compared to earlier strains. “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread,” he stated.

However, the emergence of BA.3.2 has sparked concerns about the long-term impact on public health. Andrew Pekosz, Ph.D., noted, “It has a lot of mutations that may cause it to look different to your immune system,” indicating the variant’s potential to challenge existing immunity.

Vaccination remains crucial, as it is expected to limit cases despite the variant’s mutations. Pekosz added, “Vaccination is still going to help limit cases.” Yet, the exact reasons for the resurgence of BA.3.2 are unclear, leaving many questions unanswered.

Details remain unconfirmed regarding the full implications of BA.3.2 on the pandemic landscape. As health authorities continue to monitor this variant, the public is urged to stay informed and vigilant.

The post Cicada COVID Variant BA.3.2 Spreads Across U.S. appeared first on India News.